Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy single-tablet regimen in transgender people living with HIV
2020-001070-29Phase 4Terminated
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Primary endpoint: Virologic suppression at week 48. Started Feb 2023; status: terminated.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-001070-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001070-29.